tiprankstipranks
Advertisement
Advertisement

CRSP Stock Latest News

Crispr Therapeutics Expands Autoimmune Pipeline With New CTX112 Trial
Company AnnouncementsCrispr Therapeutics Expands Autoimmune Pipeline With New CTX112 Trial
5d ago
CRSP
Crispr Therapeutics AG Slides Despite Bullish Wall Street
PremiumWeekend Updates
Crispr Therapeutics AG Slides Despite Bullish Wall Street
10d ago
CRSP
CRISPR Therapeutics: Buy Rating Reiterated as Pediatric CASGEVY Label Expands; $80 Price Target Maintained
PremiumRatings
CRISPR Therapeutics: Buy Rating Reiterated as Pediatric CASGEVY Label Expands; $80 Price Target Maintained
13d ago
CRSP
Gil Blum Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target on Pipeline Upside and 2026 Data Catalysts
PremiumRatings
Gil Blum Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target on Pipeline Upside and 2026 Data Catalysts
27d ago
CRSP
Nutrien, CAVA, Cracker Barrel, ADMA, CRISPR Trending With Analysts
PremiumWeekend Updates
Nutrien, CAVA, Cracker Barrel, ADMA, CRISPR Trending With Analysts
1M ago
NTR
ADMA
Private Markets: Bezos’ Prometheus raises $12B as OpenAI files for IPO
PremiumThe FlyPrivate Markets: Bezos’ Prometheus raises $12B as OpenAI files for IPO
1M ago
GS
TP
Crispr Therapeutics assumed at Equal Weight from Underweight at Morgan Stanley
Premium
The Fly
Crispr Therapeutics assumed at Equal Weight from Underweight at Morgan Stanley
1M ago
CRSP
Shareholders Approve New Incentive Plan and Governance Measures
Premium
Company Announcements
Shareholders Approve New Incentive Plan and Governance Measures
2M ago
8K
CRSP
FDA issues draft guidance to help accelerated cell, gene therapies for patients
PremiumThe Fly
FDA issues draft guidance to help accelerated cell, gene therapies for patients
2M ago
AZN
BMY
Crispr Therapeutics Opens New Front in Cholesterol With CTX310 Trial
PremiumCompany Announcements
Crispr Therapeutics Opens New Front in Cholesterol With CTX310 Trial
2M ago
CRSP
Crispr Therapeutics price target raised to $56 from $50 at Bernstein
PremiumThe Fly
Crispr Therapeutics price target raised to $56 from $50 at Bernstein
2M ago
CRSP
FDA Commissioner Marty Makary resigns
PremiumThe Fly
FDA Commissioner Marty Makary resigns
2M ago
AZN
BMY
Crispr Therapeutics price target raised to $76 from $74 at Evercore ISI
PremiumThe FlyCrispr Therapeutics price target raised to $76 from $74 at Evercore ISI
2M ago
CRSP
Crispr Therapeutics price target raised to $82 from $80 at Citi
Premium
The Fly
Crispr Therapeutics price target raised to $82 from $80 at Citi
3M ago
CRSP
Crispr Therapeutics price target lowered to $83 from $86 at BofA
Premium
The Fly
Crispr Therapeutics price target lowered to $83 from $86 at BofA
3M ago
CRSP
CRISPR Therapeutics Retains Buy Rating on Casgevy Momentum and 2026 Pipeline Catalysts Despite Price Target Trim to $83
PremiumRatings
CRISPR Therapeutics Retains Buy Rating on Casgevy Momentum and 2026 Pipeline Catalysts Despite Price Target Trim to $83
3M ago
CRSP
CRISPR Therapeutics: Pipeline Expansion and In Vivo CAR-T Platform Support Buy Rating; $80 Price Target Reiterated
PremiumRatings
CRISPR Therapeutics: Pipeline Expansion and In Vivo CAR-T Platform Support Buy Rating; $80 Price Target Reiterated
3M ago
CRSP
Crispr Therapeutics reports Q1 EPS ($1.28), consensus ($1.23)
PremiumThe Fly
Crispr Therapeutics reports Q1 EPS ($1.28), consensus ($1.23)
3M ago
CRSP
Reaffirming Buy on CRISPR Therapeutics: Conference Engagement and Gene-Editing Leadership Support Attractive Risk‑Reward
PremiumRatings
Reaffirming Buy on CRISPR Therapeutics: Conference Engagement and Gene-Editing Leadership Support Attractive Risk‑Reward
3M ago
CRSP
Cathie Wood’s ARK Invest Dumps $2.1M Worth of META Shares; Stock Sinks
PremiumMarket NewsCathie Wood’s ARK Invest Dumps $2.1M Worth of META Shares; Stock Sinks
4M ago
ARKF
ARKK
IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors
Premium
Market News
IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors
4M ago
BSX
IHE
Crispr Therapeutics price target raised to $110 from $105 at Piper Sandler
Premium
The Fly
Crispr Therapeutics price target raised to $110 from $105 at Piper Sandler
4M ago
CRSP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >